Therapeutic Asset Ratings

266 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Obinutuzumab Indolent Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Promethazine CLL	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Promethazine MCL	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Supcd7 Cart Cells T Lymphoblastic Leukemia/Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (47)
Anti-Bcma-Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CC (46)
Mecapegfilgrastim Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CC (46)
cd19-ucart T-Lymphoblastic Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (46)
Selinexor Acute Myeloid Leukemia, Adult	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (45)
Supcd7 Cart Cells Acute Myeloid Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (45)
zs801 Hemophilia B	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CC (45)
cd19-ucart T-Cell Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (44)
Apg-2575 Lymphoblastic Leukemia, Acute, Childhood	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Apg-2575 Refractory Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
cd180 cart Precursor B-Cell Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
cy-219 car-t Indolent B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
cy-219 car-t B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
ETOPOSIDE B Acute Lymphoblastic Leukemia/Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Lcar-Aio Cells Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Lcar-Aio Cells B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Olverembatinib Refractory Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Olverembatinib Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Promethazine Inert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
Promethazine Relapsed/Refractory B-cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
sup19 car-t B-Cell Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)
sup19 car-t Precursor B-Cell Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1	CC (43)

Showing 176 to 200 of 266 assets

PreviousPage 8 of 11Next